ONCY Latest Press Releases

-- November 4, 2026 --

Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers Globe Newswire 9:30 AM

-- October 27, 2026 --

Oncolytics Biotech Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers Globe Newswire 9:30 AM

-- October 20, 2026 --

Oncolytics Biotech to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep's Potential in Colorectal Cancer Globe Newswire 9:35 AM

-- October 14, 2026 --

Oncolytics Biotech Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment Globe Newswire 9:30 AM

-- October 12, 2026 --

Oncolytics Biotech Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update Globe Newswire 4:05 PM

-- September 29, 2026 --

Oncolytics Biotech Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy Globe Newswire 9:30 AM

-- September 28, 2026 --

Oncolytics Biotech Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study Globe Newswire 9:30 AM

-- September 11, 2026 --

Three Nasdaq Cancer Developers Under $10 Advance Clinical Programs Globe Newswire 8:45 AM

-- September 10, 2026 --

Oncolytics Biotech Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer Globe Newswire 8:15 AM

-- August 18, 2026 --

Oncolytics Biotech Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer Globe Newswire 9:00 AM

-- July 20, 2026 --

Oncolytics Biotech Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer Globe Newswire 9:00 AM

-- July 13, 2026 --

Oncolytics Biotech Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer Trial Globe Newswire 9:00 AM

-- June 16, 2026 --

Oncolytics Biotech Secures New U.S. Patent Protecting Commercial Manufacturing of Pelareorep into 2044 Globe Newswire 9:00 AM

Market Data Delayed 15 Minutes